Type 2 transglutaminase differentially modulates striatal cell death in the presence of wild type or mutant huntingtin.
Huntington's disease (HD), which is caused by an expanded polyglutamine tract in huntingtin (htt), is characterized by extensive loss of striatal neurons. The dysregulation of type 2 transglutaminase (TG2) has been proposed to contribute to the pathogenesis in HD as TG2 is up-regulated in HD brain and knocking out TG2 in mouse models of HD ameliorates the disease process. To understand the role of TG2 in the pathogenesis of HD, immortalized striatal cells established from mice in which mutant htt with a polyglutamine stretch of 111 Gln had been knocked-in and wild type (WT) littermates, were stably transfected with human TG2 in a tetracycline inducible vector. Overexpression of TG2 in the WT striatal cells resulted in significantly greater cell death under basal conditions as well as in response to thapsigargin treatment, which causes increased intracellular calcium concentrations. Furthermore, in WT striatal cells TG2 overexpression potentiated mitochondrial membrane depolarization, intracellular reactive oxygen species production, and apoptotic cell death in response to thapsigargin. In contrast, in mutant striatal cells, TG2 overexpression did not increase cell death, nor did it potentiate thapsigargin-induced mitochondrial membrane depolarization or intracellular reactive oxygen species production. Instead, TG2 overexpression in mutant striatal cells attenuated the thapsigargin-activated apoptosis. When in situ transglutaminase activity was quantitatively analyzed in these cell lines, we found that in response to thapsigargin treatment TG2 was activated in WT, but not mutant striatal cells. These data suggest that mutant htt alters the activation of TG2 in response to certain stimuli and therefore differentially modulates how TG2 contributes to cell death processes.
Ruan
Qingmin
Q
Department of Psychiatry, University of Alabama at Birmingham, Birmingham, Alabama 35294-0017, USA.
Quintanilla
Rodrigo A
RA
Johnson
Gail V W
GV
D017209:Apoptosis / Q000235:genetics / Q000502:physiology; D015153:Blotting, Western; D002118:Calcium / Q000378:metabolism; D061945:Caspase Inhibitors; D016923:Cell Death / Q000235:genetics / Q000502:physiology; D045304:Cytochromes c / Q000378:metabolism; D019204:GTP-Binding Proteins; D006801:Humans; D000071058:Huntingtin Protein; D006816:Huntington Disease / Q000235:genetics / Q000473:pathology; D007770:L-Lactate Dehydrogenase / Q000235:genetics / Q000378:metabolism; D008564:Membrane Potentials / Q000235:genetics / Q000502:physiology; D051336:Mitochondrial Membranes / Q000187:drug effects / Q000378:metabolism; D009154:Mutation / Q000502:physiology; D017072:Neostriatum / Q000166:cytology* / Q000502:physiology*; D009419:Nerve Tissue Proteins / Q000235:genetics* / Q000502:physiology*; D009687:Nuclear Proteins / Q000235:genetics* / Q000502:physiology*; D000091345:Protein Glutamine gamma Glutamyltransferase 2; D017382:Reactive Oxygen Species / Q000378:metabolism; D019284:Thapsigargin / Q000494:pharmacology; D014162:Transfection; D011503:Transglutaminases / Q000502:physiology*
D061945:Caspase Inhibitors; C086055:HTT protein, human; D000071058:Huntingtin Protein; D009419:Nerve Tissue Proteins; D009687:Nuclear Proteins; D017382:Reactive Oxygen Species; D019284:Thapsigargin; D045304:Cytochromes c; D007770:L-Lactate Dehydrogenase; D000091345:Protein Glutamine gamma Glutamyltransferase 2; D011503:Transglutaminases; D019204:GTP-Binding Proteins; D002118:Calcium